# Efficacy and Safety of ACC017 Tablets Compared With Dolutegravir Sodium Tablets in Treatment-Naïve Adults With Human Immunodeficiency Virus Type 1 (HIV-1)

> **NCT07711223** · PHASE1,PHASE2 · RECRUITING · sponsor: **Jiangsu Aidea Pharmaceutical Group Co., Ltd.** · enrollment: 660 (estimated)

## Conditions studied

- Infection, Human Immunodeficiency Virus

## Interventions

- **DRUG:** ACC017+FTC/TAF
- **DRUG:** DTG+FTC/TAF

## Key facts

- **NCT ID:** NCT07711223
- **Lead sponsor:** Jiangsu Aidea Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-07
- **Primary completion:** 2028-08-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 660 (ESTIMATED)
- **Last updated:** 2026-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07711223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07711223, "Efficacy and Safety of ACC017 Tablets Compared With Dolutegravir Sodium Tablets in Treatment-Naïve Adults With Human Immunodeficiency Virus Type 1 (HIV-1)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07711223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*